TBPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. TBPH is trading below key support (~19.05) with weakening momentum (MACD negative and expanding) and a notable spike in insider selling (+411.55% last month). While Wall Street remains bullish with raised price targets, the current tape and insider behavior don’t support an impatient “buy now” entry. I’d only turn positive if price quickly reclaims ~19.90 (pivot) and holds it.
Price/Trend: Post-market ~18.93, down -1.25% in regular hours and sitting below S1 (19.049), closer to S2 (18.525) — this is a short-term bearish setup. Momentum: MACD histogram -0.187 and negatively expanding = downside momentum strengthening. RSI: RSI(6) ~31.27, near oversold but still classified here as “neutral”; it suggests selling pressure is heavy, but it’s not a confirmed reversal signal by itself. Moving averages: Converging MAs = no clean uptrend; more consistent with a transition/weak trend rather than a strong bullish continuation. Key levels: Support 18.53 then 19.05 (now resistance after breakdown). Resistance pivot 19.90, then 20.75 and 21.27.
Intellectia Proprietary Trading Signals
support a positive longer-term narrative.
on 2026-02-26 after hours could reset expectations if profitability improves and/or guidance is strong.
Insider behavior: Insiders are selling and selling amount rose 411.55% over the last month — a meaningful negative sentiment signal.
Latest quarter: 2025/Q3. Growth: Revenue rose to $19.99M (+18.51% YoY), showing top-line improvement. Profitability: Net income fell to $3.615M (-128.47% YoY) and EPS declined to $0.07 (-126.92% YoY), indicating earnings quality/expense dynamics worsened despite higher revenue. Margin: Gross margin reported at 100 (flat YoY per provided data), but bottom-line contraction suggests operating costs/other items are the primary pressure point.
Recent trend: Bullish and improving. Two recent notes both maintained Buy ratings while raising price targets (H.C. Wainwright: $15→$20 on 2025-11-11; BTIG: $25→$40 on 2025-11-26). Wall Street pros: Revenue traction (Yupelri sales strength), potential upside from pipeline/rare-disease launch assumptions, and upward revisions to longer-term estimates. Wall Street cons: Current profitability volatility (sharp YoY net income/EPS decline) and execution risk around launches/expense levels; near-term price action is not confirming the bullish fundamental view. Influential/politician trading: No recent congress trading data available; no politician activity provided.
